Get the Stockscreener App
10.73
2.45%
-0.27
After Hours:
10.59
-0.14
-1.30%
CorMedix Inc stock is traded at $10.73, with a volume of 1.92M.
It is down -2.45% in the last 24 hours and down -16.11% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$11.00
Open:
$10.98
24h Volume:
1.92M
Relative Volume:
0.60
Market Cap:
$837.57M
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-11.66
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
-5.38%
1M Performance:
-16.11%
6M Performance:
+56.87%
1Y Performance:
+10.28%
1-Day Range:
$10.55
$11.06
1-Week Range:
$10.55
$11.71
52-Week Range:
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
10.73 | 858.65M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
Is CorMedix Inc. stock reversal real or fakeWeekly Market Report & Capital Efficiency Focused Ideas - newser.com
Backtesting results for CorMedix Inc. trading strategiesJuly 2025 Drop Watch & Accurate Intraday Trading Signals - newser.com
CorMedix: Challenging Long-Term Risk-Reward, Maintain Sell - Seeking Alpha
Analyzing recovery setups for CorMedix Inc. investorsEntry Point & Fast Moving Market Watchlists - newser.com
Is CorMedix Inc. a candidate for recovery play2025 Historical Comparison & Consistent Growth Stock Picks - newser.com
Risk adjusted return profile for CorMedix Inc. analyzedJuly 2025 Spike Watch & Safe Entry Point Identification - newser.com
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In? - sharewise.com
How cyclical is CorMedix Inc. (19KA) stock compared to rivalsJobs Report & Verified Swing Trading Watchlist - newser.com
Why CorMedix Inc. stock is in analyst buy zone2025 Institutional Moves & Consistent Profit Trade Alerts - newser.com
CorMedix (CRMD): Assessing Valuation Following Phase III REZZAYO Trial Enrollment and Melinta Growth Moves - Sahm
What analysts say about CorMedix Inc stockMoving Average Crossovers & Low Cost Market Strategies - earlytimes.in
Is a relief rally coming for CorMedix Inc. holders2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Will CorMedix Inc. (19KA) stock benefit from Fed rate cutsJuly 2025 Final Week & Risk Managed Investment Signals - newser.com
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves - The Globe and Mail
CorMedix (CRMD): Assessing Valuation After Recent Volatility and Analyst Price Targets - Yahoo Finance
What macro factors could drive CorMedix Inc. (19KA) stock higherJuly 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com
Is it too late to sell CorMedix Inc.Trade Signal Summary & Expert Verified Stock Movement Alerts - newser.com
Real time scanner hits for CorMedix Inc. explainedCEO Change & Free Community Consensus Stock Picks - newser.com
Is CorMedix Inc. building a consolidation baseDividend Hike & Smart Allocation Stock Reports - newser.com
CorMedix files to sell 6.32M shares of common stock for holders - MSN
CorMedix Bets Big On Melinta In $300 Million Deal - Finimize
CorMedix completes enrollment in phase III fungal infection study By Investing.com - Investing.com Nigeria
Cormedix announces completion of enrollment in phase III Respect clinical trial for Rezzayo - MarketScreener
CorMedix completes enrollment in phase III fungal infection study - Investing.com
Cormedix Announces Completion Of Enrollment In Phase Iii Respect Clinical Trial For Rezzayo - TradingView
CorMedix Inc. Completes Enrollment in Phase III ReSPECT Study for REZZAYO® in Fungal Infection Prophylaxis, Topline Results Expected 2Q 2026 - Quiver Quantitative
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO - Yahoo Finance
Major Clinical Trial Progress: CorMedix's REZZAYO Could Transform Blood and Marrow Transplant Care - Stock Titan
What drives CorMedix Inc stock priceSector ETF Performance & Unlock Smart Investment Tactics That Work - earlytimes.in
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):